EICHOR
● Recruiting
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Tumor Malignancies · EGFR Positive Solid Tumors · EGFR · Sponsor: Vir Biotechnology, Inc.
About this study
This Phase 1, first-in-human (FIH), dose-escalation and dose-expansion study is designed to evaluate the safety, PK, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab in participants with solid tumors that are known to express EGFR. The study will be conducted in the following 4 parts: * Part 1: VIR-5525 monotherapy dose escalation * Part 2: VIR-5525 monotherapy dose expansion * Part 3: VIR-5525 plus pembrolizumab dose escalation * Part 4: VIR-5525 plus pembrolizumab dose expansion
This description comes directly from the study's public registry record.
Talk to the study team
Study Inquiry · 1-415-654-5281 · clinicaltrials@vir.bio
Always discuss trial participation with your own doctor first.
Locations (4)
| Honor Health Research Institute | Scottsdale, Arizona, United States | Recruiting |
| MD Anderson | Houston, Texas, United States | Recruiting |
| Wollongong Hospital | Wollongong, New South Wales, Australia | Recruiting |
| Princess Alexandra Hospital | Woolloongabba, Queensland, Australia | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06960395